Discovery of new Lenalidomide derivatives as potent and selective GSPT1 degraders.

Lenalidomide / pharmacology Peptide Termination Factors / metabolism Proteomics Proteasome Endopeptidase Complex Apoptosis
Cancer GSPT1 Molecular glue Protein degradation

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
05 Oct 2023
Historique:
received: 04 05 2023
revised: 17 06 2023
accepted: 17 06 2023
medline: 19 7 2023
pubmed: 8 7 2023
entrez: 7 7 2023
Statut: ppublish

Résumé

G

Identifiants

DOI: 10.1016/j.ejmech.2023.115580 PMID: 37418973
pubmed: 37418973
pii: S0223-5234(23)00546-9
doi: 10.1016/j.ejmech.2023.115580
pii:
doi:

Substances chimiques

Lenalidomide F0P408N6V4
Peptide Termination Factors 0
Proteasome Endopeptidase Complex EC 3.4.25.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115580

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following competing financial interest (s): This work received financial support from Livzon Pharmaceutical Group Inc. And a patent was filed based on the results.

Auteurs

Yiying Wei (Y)

International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MoE) of the People's Republic of China, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.

Xinxin Xu (X)

International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MoE) of the People's Republic of China, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.

Minchuan Jiang (M)

International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MoE) of the People's Republic of China, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.

Yongxing Wang (Y)

Livzon Research Institute, Livzon Pharmaceutical Group Inc., Zhuhai, 519000, China.

Yang Zhou (Y)

International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MoE) of the People's Republic of China, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.

Zhen Wang (Z)

International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MoE) of the People's Republic of China, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.

Zhang Zhang (Z)

International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MoE) of the People's Republic of China, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China. Electronic address: zhang_zhang@jnu.edu.cn.

Fengtao Zhou (F)

International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MoE) of the People's Republic of China, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China. Electronic address: fengtaozhou@jnu.edu.cn.

Ke Ding (K)

International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development, Ministry of Education (MoE) of the People's Republic of China, College of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China; State Key Laboratory of Bioorganic & Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 345 Lingling Road, Shanghai, 200032, China. Electronic address: dingk@sioc.ac.cn.

Articles similaires

Activation of STAT3-mediated ciliated cell survival protects against severe infection by respiratory syncytial virus.

Caiqi Zhao, Yan Bai, Wei Wang et al.
1.00
STAT3 Transcription Factor Respiratory Syncytial Virus Infections Humans Animals Mice

Enhanced susceptibility of pediatric airway epithelium to respiratory syncytial virus infection.

Raymond J Pickles, Gang Chen, Scott H Randell
1.00
Respiratory Syncytial Virus Infections Humans Animals Mice STAT3 Transcription Factor

Biological functions and molecular mechanisms of exosome-derived circular RNAs and their clinical implications in digestive malignancies: the vintage in the bottle.

Yuanyan Lou, Jianing Yan, Qingqing Liu et al.
1.00
Humans RNA, Circular Exosomes Cell Proliferation Epithelial-Mesenchymal Transition

Targeting TET3 in macrophages provides a concept strategy for the treatment of endometriosis.

Hossein Hosseinirad, Md Saidur Rahman, Jae-Wook Jeong
1.00
Endometriosis Female Humans Animals Mice

Classifications MeSH

questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Isoindoles › Phtalimides › Lénalidomide › Discovery of new Lenalidomide derivatives as...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines ribosomiques › Facteurs terminaison chaîne peptidique › Discovery of new Lenalidomide derivatives as...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Protéomique › Discovery of new Lenalidomide derivatives as...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Complexes multienzymatiques › Proteasome endopeptidase complex › Discovery of new Lenalidomide derivatives as...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Discovery of new Lenalidomide derivatives as...